Riskpilot← Back to searchSign inGet full accessNORSK PHARMA AS
ASActiveOrg 913520793Myklerudveien 35, 1454 FagerstrandWholesale of other food · NACE 4638Est. 20140 employeeswww.norskpharma.no
Revenue 2024
NOK 2,1M
+207% vs 2023
EBITDA margin
-14.9%
+87% vs 2023
Equity ratio
-40.2%
Financial strength
Net profit 2024
NOK -695K
+72% vs 2023
| Revenue | NOK 2,1M | +207% |
| EBITDA | NOK -314K | +87% |
| Net profit | NOK -695K | +72% |
| Total assets | NOK 4,6M | +142% |
| Equity | NOK -1,8M | -15% |
| Employees | 0 | — |
Legal name
NORSK PHARMA AS
Org number
913520793
Legal form
Aksjeselskap
NACE code
4638 · Wholesale of other food
Founded
22. april 2014
Share capital
NOK 50 010
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Utvikling og salg av kosttilskuddsprodukter. Handelsvirksomhet innen både import og eksport, konsulentvirksomhet, kjøp og salg av eiendom. Utleie av eiendom. Kjøp og salg av selskaper samt hva hermed står i forbindelse, delta i andre selskaper med lignende virksomhet.
Address
Myklerudveien 35, 1454 Fagerstrand
Website
www.norskpharma.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 539 | 711 | 454 | 687 | 2 108 |
| Staff expenses | −0 | −0 | −0 | −0 | −114 |
| EBITDA | 11 | 172 | −329 | −2 406 | −314 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 11 | 172 | −329 | −2 406 | −314 |
| Net financials | 0 | −1 | −29 | −185 | −508 |
| Profit before tax | 11 | 172 | −358 | −2 591 | −823 |
| Tax | 10 | 38 | 37 | −114 | −128 |
| Net profit | 1 | 134 | −395 | −2 476 | −695 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 141 | 538 | 2 983 | 1 894 | 4 584 |
| Equity | 85 | 218 | 299 | −1 600 | −1 843 |
| Long-term debt | 25 | 150 | 2 446 | 3 446 | 6 239 |
| Short-term debt | 31 | 170 | 238 | 49 | 189 |
| Total debt | 56 | 320 | 2 684 | 3 495 | 6 428 |
EBITDA margin
-14.9%
This company
15.8%
Market median
-194% vs market
20202024
Equity ratio
-40.2%
This company
38.2%
Market median
-205% vs market
20202024
Return on equity
-69526100.0%
This company
18.4%
Market median
-377859339% vs market
20202024
Net profit margin
-33.0%
This company
8.1%
Market median
-507% vs market
20202024
Asset turnover
0.46×
This company
1.12×
Market median
-59% vs market
20202024
Debt / equity
3.49×
This company
0.62×
Market median
-463% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
CD Chief Executive Officer | Chief Executive Officer | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2024 | |
| Chairman | 2024 | |
| Former (3) | ||
| Board of Directors | 2024 – 2024 | |
| Board of Directors | 2021 – 2023 | |
| Board of Directors | 2021 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 89.98% | 89.98% | 2024 | |
Edwin Johan Andries Severijn | Company | 10.02% | 10.02% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NORSK PHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Christian Davidsen | Chief Executive Officer | 0 companies |
| Petter Ringwald Muri | Board of Directors | 0 companies |
| Petter Muri | Board of Directors | 0 companies |
| Henrik Renner Fredriksen | Chairman | 0 companies |
| Frank Aleksander Lunder Johansen | Board of Directors | 0 companies |
| Lars Erik Eng Eibak | Board of Directors | 0 companies |